PACE trial

The PACE Trial (formally called "Comparison of adaptive pacing therapy, cognitive behaviour therapy, graded exercise therapy, and specialist medical care for chronic fatigue syndrome (PACE): a randomised trial") was a large-scale trial to test and compare the effectiveness of four treatments for people suffering from chronic fatigue syndrome (CFS), also known as myalgic encephalomyelitis (ME).

The four treatments tested were adaptive pacing therapy (APT), cognitive behavioral therapy (CBT), Graded Exercise Therapy (GET), and standardised Specialist Medical Care (SMC). The trial found that CFS/ME patients in the CBT and GET groups had greater improvement in self-reported scores when compared to adaptive pacing or specialist care. Both the trial design and the conclusions drawn from it have been heavily criticized by patients and scientists.

A follow-up study in 2015, found "There was little evidence of differences in outcomes between the randomised treatment groups at long-term follow-up".

The PACE trial dominates clinical policy in the United Kingdom and other countries, both government funded health care and private medical insurance.

Background
The protocol paper was published in BMC Neurology in 2007. The main study was published in The Lancet in 2011. .

The principal investigators include Peter White, Trudie Chalder, and Michael Sharpe. Although not an author, Professor Simon Wessely advised the authors and provided feedback.

Professor Simon Wessely stated in November 2015 that "there are also more trials in the pipeline".

Findings
The PACE trial found that CFS/ME patients in the CBT and GET groups had greater improvement in self-reported scores when compared to adaptive pacing or specialist care.

Impact
The PACE trial and other Oxford studies have had major international impact on popular perceptions of ME/CFS and also on public policies toward treating and researching the disease.

Media


On February 27, 2011, upon the initial publication of the PACE trial, researchers Michael Sharpe and Trudie Chalder held a press conference to discuss their findings. Chalder stated, “twice as many people on graded exercise therapy and cognitive behaviour therapy got back to normal.” That assertion has been criticized for grossly overstating the study's actual findings.

The study led to press coverage around the world including The Daily Mail which stated, "Fatigued patients who go out and exercise have best hope of recovery." The New York Times declared "Psychotherapy Eases Chronic Fatigue Syndrome." According to the British Medical Journal's report on the trial, some participants were "cured."

A long-term follow-up paper was then published in The Lancet Psychiatry in October 2015. The Daily Telegraph, in a piece that was altered many days after publication under public pressure and without a formal retraction, ran a front page story with the headline, "Exercise and positivity ‘can overcome ME." The piece further reported that "Chronic Fatigue Syndrome is not actually a chronic illness and sufferers can overcome symptoms by increasing exercise and thinking positively, Oxford University has found" and quoted Sharpe describing ME as a “self-fulfilling prophesy” that happens when patients live within their limits.

In the UK the Science Media Centre is a government funded entity aimed at improving science journalism. It and reporting on the disease have been criticized for bias towards a psychological etiology for the disease and psychological studies.

Research and treatment
The PACE trial dominates clinical policy in the United Kingdom and other countries, both government funded health care and private medical insurance.

In research, PACE and other Oxford studies confound the research evidence base with studies that included patients with other conditions. It is for this reason that a 2015 report by the U.S. National Institute of Health called for the Oxford definition to be retired.

PACE and other Oxford studies also have an impact on how ME/CFS patients are treated clinically through their impact on "evidence-based" clinical guidelines. For instance, in the U.K., the primary treatment recommendations are for cognitive behavioral therapy (CBT) and graded exercise therapy (GET) based largely on the results of Oxford studies. In the U.S., a number of medical education providers, including the CDC, recommend CBT and GET and/or link poor prognosis to a belief that the disease is organic. These recommendations and findings are based on PACE or other Oxford studies.

This impact of PACE and other Oxford studies on clinical guidelines is still seen even after the 2015 Institute of Medicine report on ME/CFS, which stated that the disease was not psychological and was characterized by a systemic intolerance to even trivial activity. One example is UpToDate, whose clinical guidelines recommend the IOM criteria for diagnosis and PACE style CBT and GET for treatment, even though such treatment would be inappropriate for patients diagnosed by the IOM criteria.

Patient selection
The PACE trial used the Oxford criteria, which many patients and specialist clinicians consider to be an overly broad criteria.

Changing recovery criteria


Many critics have noted that the criteria for "recovery" on the SF-36 physical function scale, by PACE's standards, were broader than the criteria for entry, meaning that one could be simultaneously sick with "chronic fatigue syndrome" and recovered as per their recovery threshold.

In the Lancet paper, the outcome thresholds for being in the "normal range" for physical function was 60 or above, lower than the threshold for disability required to be enrolled in the trial in the first place. In a paper published in Psychological Medicine, the original recovery threshold was 85 but was later changed to 60 and above.

Outcome measures
Two critiques of outcome measures have been made. First, that the outcome measures were changed in the middle trial. Second, that only subjective measures were reported, even though the original study protocol included a six minute walking test. Critics argue that this is particularly concerning given that the trial investigators were not blind to participants' treatment assignments.

Conflicts of interest
Authors of the open letter to the Lancet criticized their failure to disclose a potential conflict of interest to trial participants.

"'The investigators violated their promise in the PACE protocol to adhere to the Declaration of Helsinki, which mandates that prospective participants be “adequately informed” about researchers’ “possible conflicts of interest.” The main investigators have had financial and consulting relationships with disability insurance companies, advising them that rehabilitative therapies like those tested in PACE could help ME/CFS claimants get off benefits and back to work. They disclosed these insurance industry links in The Lancet but did not inform trial participants, contrary to their protocol commitment. This serious ethical breach raises concerns about whether the consent obtained from the 641 trial participants is legitimate.'"

Newsletter to participants
The investigators published a newsletter for participants while the trial was still underway, which critics say could have influenced the self-reported outcomes. While the newsletter does not refer to the different treatment conditions by name, it includes positive testimonials by patients that suggest behavioral interventions:


 * “(The therapist) is very helpful and gives me very useful advice and also motivates me.”
 * “I really enjoyed being a part of the PACE Trial. It helped me to learn more about myself, especially (treatment), and control factors in my life that were damaging.

It also contained less positive assessment of research on the possibility of an infectious component, including research by Jose Montoya on herpesviruses and by John Chia on enteroviruses:


 * The laboratory work looked convincing, but many patients had significant gastro-intestinal symptoms and even signs, casting some doubt on the diagnoses of CFS being the correct or sole diagnosis in these patients.

And positive assessment of CBT:


 * "cognitive behaviour therapy was associated with an increase in grey matter of the brain and this increase was associated with improved cognitive function

Uninformed participant consent
Participants in a medical trial are typically provided with information about the trial they are considering participating in to assist them in making an informed decision, for example including any risks to them in joining the trial. In the PACE trial protocol the study investigators agreed to abide by the Helsinki convention, which includes a commitment to adequately inform trial participants of any conflicts of interest the investigators may have:

"In medical research involving competent human subjects, each potential subject must be adequately informed of the aims, methods, sources of funding, any possible conflicts of interest, institutional affiliations of the researcher, the anticipated benefits and potential risks of the study and the discomfort it may entail, and any other relevant aspects of the study."

However the investigators did not inform patients of their conflicts of interest, only stating their conflicts when the study was later published in The Lancet.

Risks and side effects
An informal survey conducted by the ME Association in 2012 showed that 80% of patients had their symptoms worsen after a course of GET.

Response to criticism
The trial investigators have defended the trial from criticism.

Professor Simon Wessely has defended the trial, one describing it as "a thing of beauty".

Controversy
The PACE Trial has been heavily criticised by patient groups and some researchers and science journalists for a number of methodological problems since its publication.

Renewed interest in the trial came in October 2015 with investigative journalist David Tuller's publication of Trial by Error, a four-part series analyzing its PACE's possible methodological weaknesses.

On October 30, 2015, the PACE trial investigators' response to these criticisms was published on the Virology Blog. .

Open letter to the Lancet
As of November 13, 2015, a total of 41 researchers have signed an open letter to the Lancet citing major flaws in the original trial publication and asking for an independent re-analysis of the individual-level PACE trial data.

The initial letter was submitted in December 2015 and included Ronald Davis, David Tuller, Vincent Racianiello, Jonathan Edwards, Leonard Jason, Bruce Levin and Arthur Reingold. The journal failed to respond.

In February 2016 the open letter was re-published with 36 additional doctors and researchers including: Dharam Ablashi, Lisa Barcellos, James Baraniuk, Lucinda Bateman, David Bell, Alison Bested, Gordon Broderick, John Chia, Lily Chu, Derek Enlander, Mary Ann Fletcher, Kenneth Friedman, David Kaufman, Nancy Klimas, Charles Lapp, Susan Levine, Alan Light, Sonya Marshall-Gradisnik, Peter Medveczky, Zaher Nahle, James Oleske, Richard Podell, Charles Shepherd, Christopher Snell, Nigel Speight, Donald Staines, Philip Stark, John Swartzberg, Ronald Tompkins, Rosemary Underhill, Rosamund Vallings, Michael VanElzakker, William Weir, Marcie Zinn and Mark Zinn.

Petitions
On November 24, 2015, MEAction launched a petition to the Lancet and Psychological Medicine calling for an independent analysis and the retraction of some of the PACE trial's conclusions. The petition was closed in February 2016, having gathered 11,897 signatures from sixty-four countries.

A US petition to the Agency for Healthcare Research and Quality (AHRQ) and the Centers for Disease Control was also launched, asking government agencies to remove guidelines and recommendations based on PACE and other studies using the Oxford definition.

Open data commitments
The study authors have been criticised for failing to follow the requirements of the Medical Research Council (who provided significant funding for the trial) to release the trial data, once anonymized.

The 2012 cost-effectiveness paper was published in the PLOS One journal. That journal requires authors, as a condition of article submission, to agree to release the anonymized trial data on request. In late 2015 Professor James Coyne made a request to the PACE authors on that basis, but the authors "converted" his request to a Freedom of Information request and refused it.

Freedom of Information requests
There have been a number of Freedom of Information requests in relation to the PACE trial made under British freedom of information laws asking that anonymized PACE trial data be released. The PACE trial investigators dismissed at least three of these claims as "vexatious"

A ruling by the UK government body the Information Commissioner's Office (ICO) on 27 October 2015 compelled Queen Mary University of London (home of the PACE trial's lead investigator Peter White to release the trial data, subject to appeal within 28 days. Three freedom of information requests from 2012 and 2013 were included in the ICO decision.

The patient consent form was also released through a Freedom of Information request.

The investigators have claimed they have received 150 freedom of information requests in relation to the PACE trial, but they are counting each piece of data requested as a request. The total number of FOI requests is 34.

Richard Horton, editor of The Lancet, stated on 18 April 2011 in an Australian radio interview "The freedom of information requests and the legal fees that have been wracked up over the years because of these vexatious claims has added another £750,000 of taxpayers’ money to the conduct of this study".

Requests from scientists
Professor James Coyne has publicly called for the trial data to be released. Professor Coyne has repeatedly criticized the PACE investigators and supporters for failing to abide by modern expectations of open-data.

Professor Coyne's request for the data was refused. The investigators deemed his request "vexatious" and accused him of "improper motive".

Ronald Davis, David Tuller, Bruce Levin, and Vincent Racaniello requested the PACE trial data in December 2015. Their request was rejected by the trial investigators.

Other calls for data release

 * 2016, PACE trial and other clinical data sharing: patient privacy concerns and parasite paranoia (Leonid Schneider, independent science journalist)
 * 2016, British patient charities Action for ME, Invest in ME, ME Association, Tymes Trust, ME Research UK, Hope 4 ME & Fibro NI and the 25 Percent ME Group have all publicly demanded the release of the trial data.
 * 2016, Canadian patient group National ME/FM Action Network have called for the data to be released.
 * 2015, Professor Andrew Gelman, a statistician at Columbia University, says "when researchers refuse to share data, and how they came up with it, they lose the right to call what they do science".
 * 2015, Richard Smith, former editor of The BMJ, called for the PACE trial data to be released.

Allegations of harassment
Criticism by patients of the trial has been rebuffed by the investigators, who have accused patents of harassment. Investigators and Professor Simon Wessely have publicly claimed they have been harassed and subjected to death threats.

Some accuse the investigators of a campaign against patients, labelling them as harassers to deflect attention, including Angela Kennedy and journalist David Tuller

Patient data breaches
In 2006 confidential PACE trial patient data was stolen from an unlocked drawer at Kings College London.

Malcolm Hooper documents in Magical Medicine how in 2005 confidential patient data was erroneously released by PACE author Professor Michael Sharpe in relation to another study.

Professor Ronald Davis, Stanford University
“I’m shocked that the Lancet published it…The PACE study has so many flaws and there are so many questions you’d want to ask about it that I don’t understand how it got through any kind of peer review.”

Dr. Bruce Levin, Columbia University
“To let participants know that interventions have been selected by a government committee ‘based on the best available evidence’ strikes me as the height of clinical trial amateurism.”

Dr. Arthur Reingold, University of California, Berkeley

 * “Under the circumstances, an independent review of the trial conducted by experts not involved in the design or conduct of the study would seem to be very much in order.”

Dr. Jonathan Edwards, University College London
“It’s a mass of un-interpretability to me…All the issues with the trial are extremely worrying, making interpretation of the clinical significance of the findings more or less impossible.”

Dr. Leonard Jason, DePaul University
“The PACE authors should have reduced the kind of blatant methodological lapses that can impugn the credibility of the research, such as having overlapping recovery and entry/disability criteria.”

Professor James Coyne, University Medical Center, Groningen

 * "The data presented are uninterpretable. We can temporarily suspend critical thinking and some basic rules for conducting randomized trials (RCTs), follow-up studies, and analyzing the subsequent data. Even if we do, we should reject some of the interpretations offered by the PACE investigators as unfairly spun to fit what has already a distorted positive interpretation of the results."
 * "The self-report measures do not necessarily capture subjective experience, only forced choice responses to a limited set of statements."
 * "One of the two outcome measures, the physical health scale of the SF-36 requires forced choice responses to a limited set of statements selected for general utility across all mental and physical conditions."
 * "Despite its wide use, the SF-36 suffers from problems in internal consistency and confounding with mental health variables. Anyone inclined to get excited about it should examine its items and response options closely. Ask yourself, do differences in scores reliably capture clinically and personally significant changes in the experience and functioning associated with the full range of symptoms of CHF?"
 * "The validity other primary outcome measure, the Chalder Fatigue Scale depends heavily on research conducted by this investigator group and has inadequate validation of its sensitivity to change in objective measures of functioning."
 * "Such self-report measures are inexorably confounded with morale and nonspecific mental health symptoms with large, unwanted correlation tendency to endorse negative self-statements that is not necessarily correlated with objective measures."

Professor Coyne spoke critically about the PACE trial at Edinburgh University in November 2015.

He spoke again about the PACE study in Belfast in February 2016 where he described it as "A wasteful trainwreck of a study". The scandal of the £5m PACE chronic fatigue trial

Professor Coyne has questioned whether the PACE trial paper could ever have been properly peer-reviewed.

James Coyne & Keith Laws
Coyne and Laws have criticised the 2015 long-term follow-up PACE trial.
 * " the overall mean short-form 36 (SF-63) physical functioning score is less than 60. It is useful to put this number in context. 77% of the PACE trial participants were women, and the mean age of the trial population was 38 years, with no other disabling medical conditions. Patients with lupus have a mean physical functioning score of 63,2 patients with class II congestive heart failure have a mean score lower than 60,3 and normal controls with no long-term health problems have a mean score of 93."

Dr. Charles Shepherd
Dr Shepherd, medical advisor to the ME Association has criticised the trial long-term follow-up.
 * "Without robust objective evidence relating to improvement and recovery, the ME patient community will continue to regard the PACE trial as a tremendous waste of research funding money"

David Tuller, Public health journalist, University of California, Berkeley

 * "The study included a bizarre paradox: participants’ baseline scores for the two primary outcomes of physical function and fatigue could qualify them simultaneously as disabled enough to get into the trial but already “recovered” on those indicators–even before any treatment. In fact, 13 percent of the study sample was already “recovered” on one of these two measures at the start of the study."
 * "In the middle of the study, the PACE team published a newsletter for participants that included glowing testimonials from earlier trial subjects about how much the “therapy” and “treatment” helped them. The newsletter also included an article informing participants that the two interventions pioneered by the investigators and being tested for efficacy in the trial, graded exercise therapy and cognitive behavior therapy, had been recommended as treatments by a U.K. government committee “based on the best available evidence.” The newsletter article did not mention that a key PACE investigator was also serving on the U.K. government committee that endorsed the PACE therapies."
 * "The PACE team changed all the methods outlined in its protocol for assessing the primary outcomes of physical function and fatigue, but did not take necessary steps to demonstrate that the revised methods and findings were robust, such as including sensitivity analyses. The researchers also relaxed all four of the criteria outlined in the protocol for defining “recovery.” They have rejected requests from patients for the findings as originally promised in the protocol as “vexatious.” "
 * "The PACE claims of successful treatment and “recovery” were based solely on subjective outcomes. All the objective measures from the trial—a walking test, a step test, and data on employment and the receipt of financial information—failed to provide any evidence to support such claims. Afterwards, the PACE authors dismissed their own main objective measures as non-objective, irrelevant, or unreliable."
 * "In seeking informed consent, the PACE authors violated their own protocol, which included an explicit commitment to tell prospective participants about any possible conflicts of interest. The main investigators have had longstanding financial and consulting ties with disability insurance companies, having advised them for years that cognitive behavior therapy and graded exercise therapy could get claimants off benefits and back to work. Yet prospective participants were not told about any insurance industry links and the information was not included on consent forms. The authors did include the information in the “conflicts of interest” sections of the published papers."
 * "The Lancet Psychiatry follow-up had null findings: Two years or more after randomization, there were no differences in reported levels of fatigue and physical function between those assigned to any of the groups.... Yet the authors, once again, attempted to spin this mess as a success."

David Tuller & Julie Rehmeyer
Tuller & Rehmeyer have written critically about PACE claims regarding the safety of Graded exercise therapy.
 * "The study’s primary case definition for identifying participants, called the Oxford criteria, was extremely broad; it required only six months of medically unexplained fatigue, with no other symptoms necessary. Indeed, 16% of the participants didn’t even have exercise intolerance—now recognized as the primary symptom of ME/CFS"
 * "After the trial began, the researchers tightened their definition of harms, just as they had relaxed their methods of assessing improvement."
 * "the study was unblinded, so both participants and therapists knew the treatment being administered. Many participants were probably aware that the researchers themselves favored graded exercise therapy and another treatment, cognitive behavior therapy, which also involved increasing activity levels. Such information has been shown in other studies to lead to efforts to cooperate, which in this case could lead to lowered reporting of harms."

Tom Kindlon
Mr Kindlon is a patient who has published extensive criticism of the PACE trial. In 2011 he published a paper on harms associated with Graded exercise therapy.

Dr Ellen Goudsmit

 * "The PACE trial was scientifically extremely poor"
 * "A treatment like GET is simply not appropriate for a disease like ME which is linked to infection and metabolic abnormalities. Given the close relationship between exertion and symptoms, it follows that asking a patient to increase their activity levels is as logical as advising smokers with lung cancer to gradually increase the number of cigarettes they smoke"

Frank Twisk
Twisk has criticised the PACE trial.
 * "The PACE trial investigated the effects of CBT and GET in chronic fatigue, as defined by the Oxford criteria, not in chronic fatigue syndrome, let alone myalgic encephalomyelitis"
 * "the positive effect of CBT and GET in subjective measures, fatigue and physical functioning, cannot be qualified as sufficient. Mean short form-36 physical functioning scores in the CBT group (62·2) and the GET group (59·8) at follow-up were below the inclusion cutoff score for the PACE trial (≤65)3 and far below the objective for recovery as defined in the PACE protocol (≥85)"
 * "The vast majority of patients improved subjectively by specialist medical care and APT to the same level as by CBT and GET, without any additional therapies, including CBT and GET, or by other therapies"
 * "looking at subjective outcomes at follow-up1 and objective outcomes in earlier studies, such as physical fitness,2 return to employment,3 social welfare benefits,3 and health-care usage,3 CBT and GET, like specialist medical care and APT, cannot be qualified as effective"

Robert Courtney

 * "Chalder and colleagues acknowledge that the trial outcomes do not support the hypothetical deconditioning model of GET for chronic fatigue syndrome"

Angela Kennedy, a sociologist of science, health, disability and medicine
Kennedy has made specific critiques of PACE regarding the following areas:

1. Serious risks to clinical patient safety caused by unsound claims made about the efficacy of CBT and GET following the PACE trial;

2. Gross discrepancies between research and clinical cohorts, and how clinical patients (and the physiological dysfunction associated with them) appear to have been actively excluded from PACE and other research by the research group involved in PACE, which has, ironically, caused serious resulting risks to clinical patient safety in the UK in particular;

3. Related to the above, gross discrepancies in how various sets of patient criteria were used (and/or rejected), including but not limited to a changing of the London criteria by PACE authors from its original state, a set of criteria which was already controversial and problematic to start with for a number of reasons;

4. Failure of the PACE trial authors to acknowledge the range and depth of scientific literature documenting serious physiological dysfunction in patients given diagnoses of ME or CFS, and how CBT and GET approaches may endanger patients in this context;

5. The inclusion of major mental illnesses in the research cohort;

6. The distortion by PACE trial researchers of 'pacing' from an autonomous flexible management strategy for patients into a therapist led Graded Activity approach;

7. The post hoc dismissal of adverse outcomes as irrelevant to the trial, in direct contradiction to what is scientifically known about the physiological dysfunctions of people given diagnoses of Myalgic Encephalomyelitis or Chronic Fatigue Syndrome ;

8. The instability of 'specialist medical care' as a treatment category, and the lack of any sound category of 'control' group.

Analysis by patient "citizen-scientists"
Graham McPhee, Tom Kindlon and others collaborated to take the results of their analyses of the PACE trial and create a set of explanatory videos to communicate the flaws that they had found.


 * The PACE Race
 * 60 - The new 75
 * Not so bad
 * The force of LOGic

Graham McPhee and Janelle Wiley also collaborated with others to create a web site summarising their critical findings.

Tom Kindlon has also has also written a larger number of e-letters and comments in response to the published papers.

MEAction has published an overview of PACE and its flaws.

Peter Kemp has written a detailed critique of the study.

Investigators
The 2011 PACE study was investigated by Peter White, KA Goldsmith, AL Johnson, L Potts, R Walwyn, JC DeCesare, HL Baber, M Burgess, LV Clark, DL Cox, Jessica Bavinton, BJ Angus, Gabrielle Murphy, M Murphy, H O'Dowd, D Wilks, P McCrone, Trudie Chalder and Michael Sharpe.

2012 Cost-effectiveness Paper
A 2012 PACE paper was published in PLOS One on cost-effectiveness.

2013 "Recovery" Paper
A PACE Trial "recovery" paper was published in Psychological Medicine in 2013. The Science Media Centre issued an "expert opinion" about the study.

Patient Graham McPhee and others created a video animation examining the results of the paper: How's that recovery?. Sam Carter applied the PACE study recovery criteria to the data from the FINE trial and questioned whether recovery had been improved six-fold by moving the threshold.

Patient advocate Peter Kemp has criticized the study, explaining how he believes the authors of the study have "twisted the SF-36 Physical Function subscale to suit their needs".

2013 Statistical Analysis Paper
This 2013 paper published in Trials Journal further examined the PACE data.

2014 Adverse Effects Paper
This 2014 paper published in the Journal of Psychosomatic Research examined adverse effects and deterioration.

2015 Secondary Mediation Analysis
This 2015 paper was published in The Lancet Psychiatry. (Trudie Chalder, Goldsmith KA, Peter White, Michael Sharpe, Pickles AR)

The paper has been criticised by Byron Hyde.



2015 Long-term Follow-up Paper
A long-term follow-up paper was then published in The Lancet Psychiatry in October 2015. .

This paper states that after 2.5 years "there were no significant differences" in outcomes between the treatment groups.

The Science Media Centre published expert opinion on the paper.

The study was criticized by James Coyne and Keith Laws as being "uninterpretable", and described the results as "null findings". The ME Association also criticized the follow-up study.

2015 Longitudinal Mediation Paper
This short paper published in Trials Journal on 16 November 2015 concludes "Approximately half of the effect of each of CBT and GET were on physical function was mediated through reducing avoidance of fearful situations".

Other Publications

 * 2014, Pain in chronic fatigue syndrome: response to rehabilitative treatments in the PACE trial
 * 2013, The planning, implementation and publication of a complex intervention trial for chronic fatigue syndrome: the PACE trial
 * 2013, Cognitions, behaviours and co-morbid psychiatric diagnoses in patients with chronic fatigue syndrome
 * 2013, Training, Supervision & Therapists' Adherence to Manual Based Therapies
 * 2011, Measuring disability in patients with chronic fatigue syndrome: reliability and validity of the Work and Social Adjustment Scale
 * 2010, Psychiatric misdiagnoses in patients with chronic fatigue syndrome

Talks & interviews

 * 2016, Dr. David Tuller discusses the flaws of the PACE trial (see also David Tuller)

Learn more

 * Wikipedia - Chronic fatigue syndrome treatment
 * 2016, ‘It was like being buried alive’: battle to recover from chronic fatigue syndrome
 * 2016, PACE trial and other clinical data sharing: patient privacy concerns and parasite paranoia
 * 2016, TULLER: PACE AUTHORS “WRAPPING THEMSELVES IN VICTIMHOOD”
 * 2016, PACE trial's forbidden fruit - is the data really poisonous?
 * 2011, Radio National Australia (April 18)
 * 2011, Expert Opinion (Science Media Centre, February 17)